Thera-SAbDab

TILDRAKIZUMAB

>   Structural Summary
TherapeuticTildrakizumab
TargetIL23A
Heavy ChainQVQLVQSGAEVKKPGASVKVSCKASGYIFITYWMTWVRQAPGQGLEWMGQIFPASGSADYNEKFEGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARGGGGFAYWGQGTLVTVSS
Light ChainDIQMTQSPSSLSASVGDRVTITCRTSENIYSYLAWYQQKPGKAPKLLIYNAKTLAEGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHHYGIPFTFGQGTKVEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Approved
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2012
INN Year Recommended2013
Companies InvolvedAlmirall S.A., Merck & Co, Schering-Plough, Sun Pharmaceutical Industries
Conditions ApprovedPlaque psoriasis
Conditions ActiveAnkylosing spondylitis, Intervertebral disc degeneration, Non-radiographic axial spondyloarthritis, Psoriatic arthritis
Conditions DiscontinuedAutoimmune disorders
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]